# Insulet

Type: Company (PODD)

Source: GetYourBrief — https://getyourbrief.com/entity/insulet
Canonical HTML page: https://getyourbrief.com/entity/insulet

## Timeline

- **2026-03-06**: IPO Pricing — MiniMed prices 28 million shares at $20.00 per share, raising $560 million.
- **2026-03-04**: Analyst Debate — Market analysts debate the valuation of the diabetes unit amid competitive pressures.
- **2026-02-24**: Initial Filing — Medtronic's diabetes unit MiniMed seeks up to $784 million in U.S. IPO.

## Recent coverage (4 stories, network-wide)

### Mid-Cap Healthcare Stocks Surge in Quant Rankings Following Earnings Season
2026-03-14 15:35:12 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Mid-cap healthcare stocks are seeing a significant re-rating as quantitative models prioritize profitable growth and upward analyst revisions. Following a strong earnings season, the diagnostic and med-tech sub-sectors have emerged as the primary drivers of sector outperformance.
Full story: https://gethealthbrief.com/story/mid-cap-healthcare-quant-rankings-2026

### Medtronic’s MiniMed Prices IPO at $20 Per Share, Raising $560 Million
2026-03-06 03:34:10 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Medtronic’s diabetes subsidiary, MiniMed Group Inc., has priced its initial public offering at $20.00 per share, successfully raising $560 million. The offering of 28 million shares comes in below initial valuation targets but marks a significant strategic pivot for parent company Medtronic plc.
Full story: https://getbiobrief.com/story/medtronic-minimed-ipo-pricing-analysis

### Corporate Resilience Shines as IAMGOLD and EQT Lead Multi-Sector Earnings Beats
2026-02-18 19:20:10 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 6

A diverse group of mid-to-large cap companies across mining, energy, and healthcare reported stronger-than-expected quarterly results, signaling robust operational efficiency. IAMGOLD and EQT Corporation headlined the session with significant revenue outperformance, reflecting strength in commodity and energy markets.
Full story: https://getfinancebrief.com/story/iamgold-eqt-earnings-beats-february-2026

### MedTech Resilience: Insulet and AtriCure Outperform Q4 Earnings Expectations
2026-02-18 19:19:07 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 6

Insulet and AtriCure reported strong quarterly results, both beating analyst estimates on top and bottom lines. These results highlight robust demand for insulin delivery systems and atrial fibrillation treatments despite broader macroeconomic pressures.
Full story: https://getbiobrief.com/story/medtech-earnings-insulet-atricure-q4-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.